Modifiable factors associated with Huntington's disease progression in presymptomatic participants
- PMID: 38855890
- PMCID: PMC11251488
- DOI: 10.1002/acn3.52120
Modifiable factors associated with Huntington's disease progression in presymptomatic participants
Abstract
Objective: Huntington's disease (HD) is a neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric symptoms. Our aim here was to identify factors that can be modified to slow disease progression even before the first symptoms appear.
Methods: We included 2636 presymptomatic individuals (comparison with family controls) drawn from the prospective observational cohort Enroll-HD, with more than 35 CAG repeats and at least two assessments of disease progression measured with the composite Huntington's disease rating Scale (cUHDRS). The association between sociodemographic factors, health behaviors, health history, and cUHDRS trajectory was assessed with a mixed-effects random forest using partial dependence plots and Shapley additive explanation method.
Results: Participants were followed by an average of 3.4 (SD = 1.97) years. We confirmed the negative impact of age and a high number of CAG repeats. We found that a high level of education, a body mass index (BMI) <23 kg/m2 before the age of 40 and >23 kg/m2 thereafter, alcohol consumption of <15 units per week, current coffee consumption and no smoking were linked to slow disease progression, as did no previous exposure to antidepressants or anxiolytic, no psychiatric history or comorbidities, and being female. Other comorbidities or marital status showed no major association with HD evolution.
Interpretation: Reducing modifiable risk factors for HD is one way to support the presymptomatic population. A high level of education, low-to-moderate alcohol consumption, no smoking, and BMI control are likely to slow disease progression in this population.
© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.Lancet Neurol. 2018 Nov;17(11):986-993. doi: 10.1016/S1474-4422(18)30294-1. Epub 2018 Sep 19. Lancet Neurol. 2018. PMID: 30243861
-
Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.Lancet Neurol. 2014 Dec;13(12):1193-201. doi: 10.1016/S1474-4422(14)70238-8. Epub 2014 Nov 3. Lancet Neurol. 2014. PMID: 25453459 Free PMC article.
-
Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease.J Neurosci. 2016 May 4;36(18):4993-5002. doi: 10.1523/JNEUROSCI.0135-16.2016. J Neurosci. 2016. PMID: 27147652 Free PMC article.
-
Prospects for neuroprotective therapies in prodromal Huntington's disease.Mov Disord. 2014 Mar;29(3):285-93. doi: 10.1002/mds.25835. Epub 2014 Feb 26. Mov Disord. 2014. PMID: 24573776 Free PMC article. Review.
-
Exploring the correlates of intermediate CAG repeats in Huntington disease.Postgrad Med. 2011 Sep;123(5):116-21. doi: 10.3810/pgm.2011.09.2466. Postgrad Med. 2011. PMID: 21904093 Review.
Cited by
-
Mitochondrial DNA leakage: underlying mechanisms and therapeutic implications in neurological disorders.J Neuroinflammation. 2025 Feb 7;22(1):34. doi: 10.1186/s12974-025-03363-0. J Neuroinflammation. 2025. PMID: 39920753 Free PMC article. Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical